TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10764173
Drug: Postoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative morphine administration in PACU
Study: 10764173
Drug: Peroperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroperative morphine titration
Study: 6619041
Drug: Mezlocillin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (18 g/day)
Study: 6619041
Drug: Carbenicillin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin (18 g/day)
Study: 28051800
Drug: Rifaximin (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (1,200 mg/day)
Study: 25079593
Drug: Endomyocardial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endomyocardial injection of BM cells (100 million, n=19)
Study: 21990263
Drug: Acetylcholine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (5-20 µg/min)
Study: 19549739
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (22.5 mg as Nitro-Bid)
Study: 11749950
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs), administered twice daily for 12 weeks or longer
Study: 2850891
Drug: Trimethoprim-polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-polymyxin B sulphate ophthalmic ointment 4-times a day for 7 days
Study: 2850891
Drug: Chloramphenicol ophthalmic
Normalized name: chloramphenicol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol ophthalmic ointment 4-times a day for 7 days
Study: 26307903
Drug: Thrice-daily human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily human regular U-500 insulin (U-500R)
Study: 26307903
Drug: Twice-daily human
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily human regular U-500 insulin (U-500R)
Study: 26307903
Drug: Thrice-daily and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily and twice-daily human regular U-500 insulin (U-500R)
Study: 21665223
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (400 mg) or ground dried fish (529 ± 109 mg)
Study: 6306060
Drug: Nabilone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (2 mg)
Study: 3002167
Drug: Prochlorperazine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (15 mg)
Study: 28032481
Drug: SER100 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER100 (10 mg)
Study: 26301645
Drug: NAC (N-acetylcysteine)
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC (N-acetylcysteine) with sustained sodium chloride regime (1 mL/kg/h for 12 hours before, during, and 6 hours after the procedure) and oral NAC at 1.2 g bid for 3 days (n = 185)
Study: 26301645
Drug: SOB (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOB (sodium bicarbonate) with abbreviated SOB regime (3 mL/kg/h 1 hour before the procedure, and 1 mL/kg/h during and 6 hours after the procedure) (n = 182)
Study: 26301645
Drug: COM (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM (combination of abbreviated SOB regime and oral NAC) (n = 181)
Study: 19508995
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of BMMNC (n = 41)
Study: 16396971
Drug: Intravenous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous darbepoetin alfa (32.1 microg/week)
Study: 16396971
Drug: Subcutaneous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous darbepoetin alfa (34.1 microg/week)
Study: 14607958
Drug: C5a receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: C5a receptor antagonist (10 mg/kg/day peroral, 0.3 mg/kg/day s.c.)
Study: 14607958
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg/day s.c.)
Study: 14607958
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg i.v.)
Study: 14607958
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of C5a antagonist and prednisolone
Study: 14607958
Drug: Colitis control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colitis control (drug-free)
Study: 8930228
Drug: 1500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/d CNA (ENDURACIN) for 2 months
Study: 8930228
Drug: 2000 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg/d CNA for 2 months
Study: 1357453
Drug: Famotidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (10 mg bolus followed by 3.2 mg/h intravenously for 72 hours)
Study: 31086947
Drug: Control (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hepatitis E vaccine)
Study: 29749688
Drug: Constraint‐induced aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced aphasia therapy (CIAT)
Study: 29749688
Drug: Stimulation aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation aphasia therapy (SAT)
Study: 22057730
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of water (control)
Study: 16052584
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (etanercept and infliximab)
Study: 12444542
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg daily, increased to 10 mg daily if necessary after 6 weeks)
Study: 12444542
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg daily, increased to 60 mg daily if necessary after 6 weeks)
Study: 7020194
Drug: Irradiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation of the larynx and all neck nodes (T+N), tumor dose 5130 rad/6‐7 weeks
Study: 7020194
Drug: Irradiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation of the laryngeal portals only (T), tumor dose 5130 rad/5 weeks
Study: 26540987
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapies and autologous BM-MNC transplantation
Study: 10547405
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapies
Study: 21170641
Drug: Calcium-fortified ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-fortified ice cream containing 96, 244, 459 or 676 mg calcium daily for 28 days
Study: 21170641
Drug: Calcium-fortified ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-fortified ice cream (244 mg calcium preparation)
Study: 10509847
Drug: Cefdinir 14
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 14 mg/kg QD
Study: 11144398
Drug: Cefdinir 7
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 7 mg/kg BID
Study: 10509847
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 10 mg/kg 4 times daily
Study: 8568623
Drug: Sublingual oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual oxytocin (400 int. units / 684 micrograms)
Study: 8568623
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (1 int. unit / 1.71 micrograms)
Study: 7006790
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with 5-FU (9 mg/kg intravenously for five consecutive days) and CCNU (70 mg/m2 orally on the first day of each course).
Study: 7006790
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (control group).
Study: 7006790
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with 5-FU and CCNU.
Study: 28506979
Drug: Ezetimibe added
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe added to simvastatin therapy
Study: 21355446
Drug: New pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pharmaceutical equivalent tablet formulation containing 300 mg of TDF
Study: 9893184
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy with 7 preseasonal injections of molecular standardized allergens from grass and rye pollen
Study: 8751095
Drug: Buffer solution
Normalized name: Buffer Solution, pH 5.00, Reference Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer solution (control)
Study: 7029275
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of vitamin E per kilogram of body weight per day
Study: 31011868
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri 4659 (L. reuteri) plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus L. reuteri/bid for 10 days
Study: 31011868
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus placebo/bid for 10 days
Study: 29078109
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health checklist intervention
Study: 11919404
Drug: Standard Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Heparin
Study: 10607234
Drug: Combined prednisolone/interferon‐alpha2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined prednisolone/interferon‐alpha2b (IFN‐alpha2b) therapy
Study: 10607234
Drug: Interferon‐alpha2b (IFN‐alpha2b)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐alpha2b (IFN‐alpha2b) therapy
Study: 7642417
Drug: Simultaneous chemoradiation
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous chemoradiation therapy (cisplatin 30 mg/m2 for 3 days, etoposid 80 mg/m2 for 3 days, 5-fluorouracil 900 mg/m2 for 4 days, radiation therapy 2 Gy twice a day for 5 days)
Study: 7642417
Drug: Simultaneous chemoradiation
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous chemoradiation therapy
Study: 25241107
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (6-g bolus followed by 2 g/hour infusion for up to 12 hours)
Study: 19264239
Drug: <2-h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: <2-h infusion of eptifibatide
Study: 19264239
Drug: 18-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18-h infusion of eptifibatide
Study: 17546553
Drug: Lepirudin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lepirudin (0.25 mg/kg b. w. bolus and 0.2 mg/kg b. w. added to the CPB priming)
Study: 17546553
Drug: Heparin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (400 U/kg b. w. bolus with protamine reversal)
Study: 15483780
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.8 g/kg/day) for diabetic patients
Study: 15483780
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g/kg/day) for nondiabetic patients
Study: 11280671
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 microg/puff) with low inspiratory flow rate (0.6 l/s)
Study: 11280671
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 microg/puff) with high inspiratory flow rate (1.2 l/s)
Study: 9470565
Drug: Tartar-control dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartar-control dentifrice (containing tetrapotassium pyrophosphate, PEG‐6, disodium pyrophosphate, and tetrasodium pyrosulphate in a 5.0% soluble pyrophosphate formulation)
Study: 7930696
Drug: CD4-PE40 infusions
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4-PE40 infusions
Study: 3150630
Drug: Thymostimulin (TST)
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TST) plus chemotherapy
Study: 27573562
Drug: Pictilisib (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictilisib (260 mg daily on days 1-5 every week) with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Study: 27573562
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Study: 26571324
Drug: Thermal balancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal balancing therapy using a Therapeutic Device for 6 months
Study: 20373114
Drug: Somatostatin (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (high-dose infused over 12 h)
Study: 20373114
Drug: Somatostatin (pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (pancreatic duct injection)
Study: 20373114
Drug: Octreotide (high-dose)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (high-dose)
Study: 20373114
Drug: Octreotide (pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (pancreatic duct injection)
Study: 18442357
Drug: Isoflavone-intact soya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-intact soya protein (active treatment)
Study: 15722803
Drug: Cognitive-behavioral intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral intervention and preventive physical therapy
Study: 15722803
Drug: Minimal Treatment
Normalized name: Minimally modified low density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Treatment Group (examination, reassurance, and activity advice)
Study: 12666111
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 10 gm daily
Study: 8558219
Drug: CMFVP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFVP (cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 intravenously weekly for 1 year, fluorouracil 400 mg/m2 intravenously weekly for 1 year, vincristine 0.625 mg/m2 intravenously weekly for the first 10 weeks, and prednisone weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2)
Study: 6650108
Drug: Brief courses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief courses of antibiotics active against major contaminating bacterial pathogens given prior to surgery
Study: 6650108
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration of antibiotics after surgery
Study: 29324539
Drug: Nurse-led telephone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led telephone intervention (Optimal Personalised Care After Treatment-Gynaecological)
Study: 17414467
Drug: Accelerated multimodality
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated multimodality treatment program including a 12-day induction course of radiation (1.5 Gy twice daily to a total of 30 Gy) concurrent with continuous intravenous infusions of cisplatin (20 mg/m2 per day) and 5-fluorouracil (1000 mg/m2 per day), followed by surgery and a second course of chemoradiotherapy.
Study: 17414467
Drug: Accelerated multimodality
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated multimodality treatment program
Study: 15114104
Drug: Both HTK
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HTK and UW solutions
Study: 11599601
Drug: Marinol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marinol (15 mg)
Study: 11599601
Drug: Smoked THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked THC (16.88 mg) in a placebo marijuana cigarette
Study: 10984320
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone substitution therapy
Study: 8055724
Drug: Narcotics (intramuscular/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotics (intramuscular/oral analgesics) after overnight hospital stay
Study: 8055724
Drug: SQMP (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQMP (subcutaneous infusion of morphine sulfate via home infusion pump)
Study: 233889
Drug: Saturated free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated free fatty acids (C3 to C18) applied daily under occlusive patch tests
Study: 233889
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (C18 unsaturated fatty acid) applied daily under occlusive patch tests
Study: 30153126
Drug: Subcutaneous local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous local anesthesia (group S)
Study: 24672620
Drug: Compressor-administered defibrillation
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressor-administered defibrillation
Study: 24672620
Drug: Facilitator-administered defibrillation
Normalized name: sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facilitator-administered defibrillation
Study: 22959807
Drug: Temoporfin mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temoporfin mediated photodynamic therapy (PDT) - Arm A: 0.15 mg/kg Foscan; 96 h drug-light interval
Study: 22959807
Drug: Temoporfin mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temoporfin mediated photodynamic therapy (PDT) - Arm B: 0.10 mg/kg; 48 h drug-light interval
Study: 22959807
Drug: Temoporfin mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temoporfin mediated photodynamic therapy (PDT) - Arm C: 0.075 mg/kg; 24 h drug-light interval
Study: 22959807
Drug: Temoporfin mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temoporfin mediated photodynamic therapy (PDT) - All arms
Study: 19374210
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of hyperbaric S75:R25 bupivacaine (10 mg)
Study: 19374210
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of hyperbaric S75:R25 bupivacaine (12 mg)
Study: 19374210
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of hyperbaric S75:R25 bupivacaine (16 mg)
Study: 19374210
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of hyperbaric S75:R25 bupivacaine (20 mg)
Study: 8582461
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg at 10:00 h
Study: 8582461
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg at 22:00 h
Study: 2206038
Drug: Fructans (FAs)
Normalized name: fructone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructans (FAs) isolated from Jerusalem artichokes, 20 g dose
Study: 2206038
Drug: Fructans (FAs)
Normalized name: fructone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructans (FAs) added to a wheat-starch meal, 10 g FA with 50 g wheat-starch
Study: 209710
Drug: Four-drug combination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug combination chemotherapy (vincristine, CCNU, cyclophosphamide, methotrexate)
Study: 209710
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination chemotherapy (CCNU, cyclophosphamide, methotrexate)
Study: 24674827
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with 1.0 g cefazolin intravenously 30 minutes before incision
Study: 15117570
Drug: 0.1% pemirolast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% pemirolast potassium ophthalmic solution dosed twice daily (b.i.d.)
Study: 15117570
Drug: 0.1% pemirolast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% pemirolast potassium ophthalmic solution dosed four times daily (q.i.d.)
Study: 8129435
Drug: Ceftriaxone 100
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 100 mg/kg intravenously followed by a single dose of 50 mg/kg 24 hours later
Study: 8129435
Drug: Chloramphenicol 40
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol 40 mg/kg intravenously, then 25 mg/kg eight hourly for five days
Study: 379936
Drug: Levamisole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (3 days every 2 weeks, 1.1-3.8 mg/kg per day, fixed dose of 3 x 50 mg)
Study: 16398702
Drug: NBI-6024 (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-6024 (five biweekly subcutaneous injections)
Study: 1859293
Drug: Aspirin (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (exact dosage not specified)
Study: 6643333
Drug: Intramuscular (im)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (im) administration of 500 mg
Study: 6643333
Drug: Intravenous (iv)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (iv) administration of 500 mg
Study: 24057039
Drug: Single-use injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-use injection device (SID)
Study: 8078449
Drug: Nutrition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition therapy
Study: 18394022
Drug: Simvastatin/Ezetimibe 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/Ezetimibe 10 mg/10 mg